Trial reportJournal of human hypertension2010
Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.
Trial report in Journal of human hypertension, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00343551 (A Nine-week, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren 300 mg Compared to Irbesartan 300 mg and Ramipril 10 mg in the Setting of a Missed Dose in Patients With Essential Hypertension), which is not on this map. Cited by 23 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Nine-week, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren 300 mg Compared to Irbesartan 300 mg and Ramipril 10 mg in the Setting of a Missed Dose in Patients With Essential Hypertension
Who cites it
23 citing papers in PubMed, 4 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Renin inhibitors versus angiotensin receptor blockers for primary hypertension.The Cochrane database of systematic reviews · 2025Pooled it
- Efficacy of angiotensin receptor blockers for nocturnal blood pressure reduction: a systematic review and meta-analysis.Annals of medicine · 2024Pooled it
- Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension.The Cochrane database of systematic reviews · 2020Pooled it
- Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis.European heart journal · 2014Pooled it
- Effects of aliskiren- and ramipril-based treatment on central aortic blood pressure in elderly with systolic hypertension: a substudy of AGELESS.Vascular health and risk management · 2014Trial
- Addition of aliskiren to Angiotensin receptor blocker improves ambulatory blood pressure profile and cardiorenal function better than addition of benazepril in chronic kidney disease.International journal of molecular sciences · 2013Trial
- Sustained blood pressure-lowering effect of aliskiren compared with telmisartan after a single missed dose.Journal of clinical hypertension (Greenwich, Conn.) · 2013Trial
- Developing decision support algorithm for hypertension medications for use in a digital therapeutic system.Frontiers in drug safety and regulation · 2025Article
- How drug onset rate and duration of action affect drug forgiveness.Journal of pharmacokinetics and pharmacodynamics · 2024Article
- Article
- In silico profiling of systemic effects of drugs to predict unexpected interactions.Scientific reports · 2018Article
- Is There a Threshold for Medication Adherence? Lessons Learnt From Electronic Monitoring of Drug Adherence.Frontiers in pharmacology · 2018Article
- Aliskiren increases aquaporin-2 expression and attenuates lithium-induced nephrogenic diabetes insipidus.American journal of physiology. Renal physiology · 2017Article
- Renin Inhibition with Aliskiren: A Decade of Clinical Experience.Journal of clinical medicine · 2017Review
- Efficacy, safety, and tolerability of antihypertensive therapy with aliskiren/amlodipine in clinical practice in Austria. The RALLY (Rasilamlo long lasting efficacy) study.Wiener klinische Wochenschrift · 2015Observational
- Renin inhibitors in diabetes and hypertension: an update.EXCLI journal · 2014Review
- Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials.Therapeutic advances in chronic disease · 2013Article
- Aliskiren/amlodipine as a single-pill combination in hypertensive patients: subgroup analysis of elderly patients, with metabolic risk factors or high body mass index.Journal of drug assessment · 2013Article
- Direct renin inhibition: from pharmacological innovation to novel therapeutic opportunities.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2011Review
- Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension.Drugs · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most patients inadvertently miss an occasional dose of antihypertensive therapy, and hence drugs that provide sustained blood-pressure (BP) reduction beyond the 24-h dosing interval are desirable. The primary objective of this study was to compare the 24-h mean ambulatory BP reductions from baseline after a simulated missed dose of the direct renin inhibitor aliskiren, irbesartan or ramipril. In this double-blind study, 654 hypertensive patients (24-h mean ambulatory diastolic BP (MADBP) >or=85 mm Hg) were randomized 1:1:1 to once-daily aliskiren 150 mg, irbesartan 150 mg or ramipril 5 mg. Doses were doubled after 2 weeks. At day 42, patients were again randomized equally within each group to receive 1 day of placebo ('missed dose') on either day 42 or day 49. Patients with a successful 24-h ambulatory BP measurement at baseline and on day 42/49 were included in the analyses. The 24-h mean ambulatory systolic BP (MASBP)/MADBP reductions from baseline after a missed dose of aliskiren 300 mg (9.3/7.0 mm Hg) were similar to irbesartan 300 mg (9.5/7.3 mm Hg) and significantly larger than ramipril 10 mg (7.1/5.0 mm Hg, P<or=0.008). Loss of BP-lowering effect with aliskiren in the 24 h after a missed dose (1.0/0.7 mm Hg for 24-48-h vs 0-24-h MASBP/MADBP) was significantly lower than with irbesartan (3.6/2.2 mm Hg, P<0.01) or ramipril (4.0/2.6, P<0.0001). This equates to maintenance of 91/91% of the MASBP/MADBP-lowering effect with aliskiren, greater than irbesartan (73/77%) or ramipril (64/65%). The incidence of adverse events was similar across treatments (32.9-36.0%), although ramipril treatment was associated with an increased incidence of cough (ramipril, 6.1%; aliskiren, 0.5%; irbesartan, 1.8%). Aliskiren 300 mg provided a sustained BP-lowering effect beyond the 24-h dosing interval, with a significantly smaller loss of BP-lowering effect in the 24-48 h period after dose than irbesartan 300 mg or ramipril 10 mg.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.